GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Other Assets for Insurance Companies

Tvardi Therapeutics (LTS:0HTC) Other Assets for Insurance Companies


View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Other Assets for Insurance Companies?

Other Assets for Insurance Companies only applies to insurance companies.


Tvardi Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Website
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.